title: Efficacy of enrofloxacin in a mouse model of sepsis.
abstract: We examined the efficacy of enrofloxacin administered by 2 different routes in a mouse model of sepsis. Male CD1 mice were infected with a bioluminescent strain of enteropathogenic Escherichia coli and treated with enrofloxacin either by injection or in drinking water. Peak serum levels were evaluated by using HPLC. Mice were monitored for signs of clinical disease, and infections were monitored by using bioluminescence imaging. Serum levels of enrofloxacin and the active metabolite ciprofloxacin were greater in the group treated by injection than in controls or the groups treated by administration in drinking water. Survival of the group treated with enrofloxacin injection was greater than that of controls and groups treated with enrofloxacin in the drinking water. Bioluminescence in the group treated with enrofloxacin injection was less than that in the groups treated with oral administration at 12 h and in the groups treated orally and the control group at 16 h. According to these findings, we recommend the use of injectable enrofloxacin at 5 mg/kg SC for mice with systemic infections.
authors.affiliation: Division of Comparative Medicine, University of South Florida, Tampa, Florida, USA.
authors.forename: Andrea R
authors.initials: AR
authors.lastname: Slate
authors.affiliation: Laboratory of Transfusion Biology, Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
authors.forename: Sheila
authors.initials: S
authors.lastname: Bandyopadhyay
authors.affiliation: Perkin Elmer, Alameda, California, USA.
authors.forename: Kevin P
authors.initials: KP
authors.lastname: Francis
authors.affiliation: Department of Molecular Biomedical Sciences, North Carolina State University College of Veterinary Medicine, Raleigh, North Carolina, USA.
authors.forename: Mark G
authors.initials: MG
authors.lastname: Papich
authors.affiliation: Institute of Comparative Medicine, Columbia University, New York, New York, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Karolewski
authors.affiliation: Laboratory of Transfusion Biology, Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
authors.forename: Eldad A
authors.initials: EA
authors.lastname: Hod
authors.affiliation: Laboratory of Transfusion Biology, Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, New York, USA; Institute of Comparative Medicine, Columbia University, New York, New York, USA.
authors.forename: Kevin A
authors.initials: KA
authors.lastname: Prestia
mesh_terms: D061605:Administration, Intravenous; D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000077422:Enrofloxacin; D004926:Escherichia coli / Q000502:physiology*; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control / Q000662:veterinary*; D024841:Fluoroquinolones / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D018805:Sepsis / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control / Q000662:veterinary*
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D000077422:Enrofloxacin